BSD Medical Reports Hyperthermia Clinical Study on Pancreatic Cancer Highlighted at Society of Thermal Medicine Conference

SALT LAKE CITY--(BUSINESS WIRE)-- BSD Medical Corporation (NASDAQ: BSDM) ("Company" or "BSD") (www.BSDMedical.com), a leading provider of medical systems that utilize heat therapy to treat cancer, reported today that an important Phase III clinical study, hyperthermia in combination with chemotherapy for the treatment of pancreatic cancer patients, was the subject of a press release issued by The Society of Thermal Medicine (STM) (http://psfebus.allenpress.com/eBusSFTM/). STM highlighted initiation of the Hyperthermia European Adjuvant Trial (HEAT) during its 29th Annual Conference, which was held in Portland, Ore. The randomized, multicenter, Phase III study, sponsored by the Munich Groshadern University Medical School (UMS) and the European Society for Hyperthermic Oncology, compares hyperthermia with chemotherapy (gemcitabine plus cisplatin) to chemotherapy (gemcitabine) alone. Patients are randomized following standard surgical resection of the tumor. The study is open for enrollment of 350 patients and has already enrolled the first three patients. Patient enrollment is expected to proceed quickly. The principal investigators are Rolf D. Issels, MD PhD, and Katharina Lechner, MD, from the Munich Grosshadern UMS, Munich, Germany.

The following clinical sites will initially participate in the clinical study: Munich Grosshadern UMS, Munich, Klinik Bad Trissl, Oberaudorf, Red Cross Hospital, Munich, UMS Düsseldorf, UMS Erlangen and UMS Tübingen, all Germany. These sites all utilize the BSD-2000 Hyperthermia System.

Pancreatic cancer is one of the deadliest and most difficult to treat cancers and is the fourth leading cause of cancer-related death in the U.S. and throughout the world. There will be an estimated 44,000 Americans and 60,000 Europeans diagnosed with pancreatic cancer during 2012. The median survival is approximately 6 months for patients with metastatic disease and 10 months for patients with locally advanced disease. Median survival after 5 years is <5% of all patients. Advanced pancreatic cancer patients currently have few treatment options.

About the Society for Thermal Medicine

The Society for Thermal Medicine (STM) was founded in 1986 as a professional society to significantly improve treatment outcomes by advancing the science, development and application of thermal therapy. STM is a premier, international scientific forum for fostering interaction and innovation in the study of biological, physical and medical applications of thermal therapy for cancer and other diseases. STM promotes rapid dissemination of exciting scientific breakthroughs in thermal medicine in order to expedite the translation of both basic and applied research to the clinic for the immediate benefit of patients. STM also sponsors high quality forums for education of medical professionals in the practice of thermal medicine.

About BSD Medical Corporation

BSD Medical Corporation develops, manufactures, markets and services systems to treat cancer and benign diseases using heat therapy delivered using focused radiofrequency (RF) and microwave energy. BSD’s product lines include both hyperthermia and ablation treatment systems. BSD’s hyperthermia cancer treatment systems, which have been in use for many years in the United States, Europe and Asia, are used to treat certain tumors with heat (hyperthermia) while increasing the effectiveness of other therapies such as radiation therapy. BSD’s microwave ablation system has been developed as a stand-alone therapy to ablate and destroy soft tissue. The Company has developed extensive intellectual property, multiple products in the market and established distribution in the United States, Europe and Asia. Certain of the Company’s products have received regulatory approvals in the United States, Europe and China. For further information visit BSD Medical's website at www.BSDMedical.com.

Statements contained in this press release that are not historical facts are forward-looking statements, as defined in the Private Securities Litigation Reform Act of 1995. All forward-looking statements are subject to risks and uncertainties detailed in the Company's filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date on which such statements are made, and the Company undertakes no obligation to update such statements to reflect events or circumstances arising after such date.



CONTACT:

BSD Medical Corporation
Dennis Gauger, 801-972-5555
[email protected]
fax: 801-972-5930

KEYWORDS:   United States  Europe  North America  Germany  Oregon  Utah

INDUSTRY KEYWORDS:   Health  Clinical Trials  Hospitals  Medical Devices  Oncology  Radiology  General Health

MEDIA:

Logo
 Logo

Suggested Articles

The profit margins and management of Community Health Group raise questions about oversight of managed care insurers.

Financial experts are warning practices about the pitfalls of promoting medical credit cards to their patients.

A proposed rule issued by HHS on Tuesday would expand short-term coverage, a move Seema Verma said will have "virtually no impact" on ACA premiums.